Bavarian Nordic AS
BV3
Company Profile
Business description
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
Contact
Philip Heymans Alle 3
Hellerup2900
DNKT: +45 33268383
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,861
Stocks News & Analysis
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,882.40 | 73.80 | -0.82% |
| CAC 40 | 8,123.41 | 31.50 | -0.39% |
| DAX 40 | 25,410.63 | 168.22 | -0.66% |
| Dow JONES (US) | 51,511.59 | 352.10 | -0.68% |
| FTSE 100 | 10,705.26 | 3.07 | -0.03% |
| HKSE | 24,704.75 | 129.37 | -0.52% |
| NASDAQ | 26,936.04 | 308.24 | -1.13% |
| Nikkei 225 | 65,684.56 | 665.61 | 1.02% |
| NZX 50 Index | 13,758.88 | 62.88 | -0.45% |
| S&P 500 | 7,706.03 | 58.61 | -0.75% |
| S&P/ASX 200 | 8,688.80 | 76.50 | -0.87% |
| SSE Composite Index | 3,900.00 | 36.52 | -0.93% |